22 July, 2017 by The TZ Newswire Staff Comments Off on Tennis star John McEnroe sells Hamptons estate
Tennis star John McEnroe sells Hamptons estate
Fault! Tennis legend John McEnroe attempted to ace his Southampton estate, but buyers weren’t having it. His 8,000-square-foot beach house sold for $11.25 million last month — quite a bit under the original ask. McEnroe was initially asking $14.5 million for the vacation house when it first hit the market in May 2016. Nevertheless, the deal still lined his pockets. He and his wife, singer and songwriter Patty Smyth, bought the house for $4.2 million in 1999, according […]
22 July, 2017 by The TZ Newswire Staff Comments Off on NewsWatch: Alphabet earnings: A $2.74 billion hit for Google, potential YouTube results for investors
NewsWatch: Alphabet earnings: A $2.74 billion hit for Google, potential YouTube results for investors
As it gears up for a second-quarter earnings report scheduled for Monday, Alphabet Inc.
22 July, 2017 by The TZ Newswire Staff Comments Off on 12 Things You Didn’t Know About Sturm, Ruger & Company, Inc.
12 Things You Didn’t Know About Sturm, Ruger & Company, Inc.
Sturm, Ruger, & Co. (NYSE: RGR) may not have the same storied history as rival Smith & Wesson, but that doesn’t mean the gunslinger isn’t an interesting case study all by itself. There’s a reason millions love Ruger guns, after all.
Following are 12 things you just might not know about Sturm, Ruger, and why they’re so important to it today.
Image source: Sturm, Ruger.
22 July, 2017 by The TZ Newswire Staff Comments Off on Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
Celgene (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) are two big biotechs facing dramatically different outlooks for the future. Their stock prices reflect that reality. Celgene’s share price is up more than 30% over the last 12 months, while Gilead stock is down by a double-digit percentage during the same period.
But the past is the past. Which of these biotech stocks is the better buy for investors now? Here’s how Celgene and Gilead Sciences compare.
Image source: Getty Images.
22 July, 2017 by The TZ Newswire Staff Comments Off on Mueller Tries To Turn Manafort In Trump Russia Probe
Mueller Tries To Turn Manafort In Trump Russia Probe
Special Counsel Robert Mueller’s full-court press on anyone and everyone involved with the Trump campaign has finally begun – and the first target in his sights is, of course, former Trump Campaign Manager Paul Manafort, by far the easiest mark. According to Reuters, Mueller and his team are trying to recruit Manafort as a cooperating witness in the Russia investigation in exchange for immunity for possible money laundering charges.
22 July, 2017 by The TZ Newswire Staff Comments Off on 3 Republican Healthcare Reforms Democrats May Agree To, and 1 Major Sticking Point
3 Republican Healthcare Reforms Democrats May Agree To, and 1 Major Sticking Point
When Donald Trump became president in January, it was widely assumed that the Affordable Care Act (ACA) was running on borrowed time. However, the ACA, which is more commonly known as Obamacare, lives on. Despite four separate attempts to repeal and replace Obamacare by Congressional Republicans — two in the House and two in the Senate — Obamacare remains the health law of the land.
22 July, 2017 by The TZ Newswire Staff Comments Off on Game Theory Starts to Weigh on OPEC’s Production Cuts
Game Theory Starts to Weigh on OPEC’s Production Cuts
Last week, CSX Corporation (NASDAQ: CSX) fell 5% in one day when CEO Hunter Harrison announced not only his plans to leave the company but also some serious doubts about the company’s future.
On this episode of Industry Focus: Energy, analysts Taylor Muckerman and Sean O’Reilly explain what has Harrison so disillusioned with CSX’s prospects, and whether or not the rest of the railway sector should be worried, too.